ICER mulls GSK COPD drugs ahead of next Medicare negotiation

The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.